| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/17/2009 | WO2009112615A1 Pharmaceutical composition for inhibiting the transcription factor inducible by hypoxia, modulators of pathological processes of angiogenesis, oncogenesis, inflammation, apoptosis, and cellular therapy |
| 09/17/2009 | WO2009112609A1 Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof |
| 09/17/2009 | WO2009112568A1 Novel quinolinylamide derivatives useful as modulators of dopamine and serotonin receptors |
| 09/17/2009 | WO2009112565A1 Thiazolyl-dihydro-indazoles |
| 09/17/2009 | WO2009112550A1 Novel n-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
| 09/17/2009 | WO2009112541A2 [2-(6-flouro-1h-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders |
| 09/17/2009 | WO2009112529A1 Novel method for the production of sulphonylpyrroles as hdac inhibitors |
| 09/17/2009 | WO2009112524A1 Pyridopyrimidines as plk1 ( polo-like kinase) inhibitors |
| 09/17/2009 | WO2009112522A1 (E)-N-(2-Amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide salts |
| 09/17/2009 | WO2009112493A1 Formulation and method for the prevention and treatment of bone metastases or other bone diseases |
| 09/17/2009 | WO2009112490A1 Sulfonamides as zap-70 inhibitors |
| 09/17/2009 | WO2009112475A1 Pyrrolo [2, 3-b] pyridin derivatives as ikk2 inhibitors |
| 09/17/2009 | WO2009112473A1 Novel compounds |
| 09/17/2009 | WO2009112462A2 Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators |
| 09/17/2009 | WO2009112461A1 Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors |
| 09/17/2009 | WO2009112460A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors |
| 09/17/2009 | WO2009112459A1 Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| 09/17/2009 | WO2009112455A1 Medium chain dicarboxylic acids, their derivates and metabolic disorders |
| 09/17/2009 | WO2009112445A1 Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| 09/17/2009 | WO2009112439A1 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
| 09/17/2009 | WO2009112436A1 Modified release composition comprising doxofylline |
| 09/17/2009 | WO2009112395A1 2-aminoquinolines as 5-ht5a receptor antagonists |
| 09/17/2009 | WO2009112361A2 Synbiotic mixture |
| 09/17/2009 | WO2009112274A2 Novel dosage and formulation |
| 09/17/2009 | WO2009112273A2 Novel dosage and formulation |
| 09/17/2009 | WO2009112266A1 Active substance combination with gemcitabine for the treatment of epithelial cancer |
| 09/17/2009 | WO2009112258A1 Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate |
| 09/17/2009 | WO2009112232A2 New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
| 09/17/2009 | WO2009112231A2 New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen |
| 09/17/2009 | WO2009112226A1 Formulations with sanguinarine, chelerythrine or chelidonine for the treatment of warts, verrucas and psoriatic plaques |
| 09/17/2009 | WO2009112155A1 Heteroaryl-substituted dicyanopyridines and use thereof for treatment of cardiovascular diseases |
| 09/17/2009 | WO2009112139A1 Azaindole compounds for treatment of central nervous system disorders |
| 09/17/2009 | WO2009112033A1 Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse |
| 09/17/2009 | WO2009112022A2 Pharmaceutical composition for the diagnosis or treatment of diseases associated with zinc finger proteins |
| 09/17/2009 | WO2009112021A2 Pharmaceutical composition for the diagnosis or treatment of a plasmocytoma |
| 09/17/2009 | WO2009111998A2 Specific impurities of montelukast |
| 09/17/2009 | WO2009111948A1 The salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione or its derivatives, their polymorphs, preparation methods and uses thereof |
| 09/17/2009 | WO2009111947A1 Crystalline 1-(3-fluorophenyl)-5-methyl-2-(1h)pyridone, the preparation methods, compositions and applications thereof |
| 09/17/2009 | WO2009111943A1 The compounds as the estrogen related receptors modulators and the uses thereof |
| 09/17/2009 | WO2009111893A1 Substituted pyrimidine compounds and their use as ifnar mediators |
| 09/17/2009 | WO2009111873A1 Stabilized 1,25-dihydroxyvitamin d2 and method of making same |
| 09/17/2009 | WO2009111868A1 Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist |
| 09/17/2009 | WO2009111852A2 Process to obtain a pharmaceutical composition of retinoids, derivative product of retinoids and its use |
| 09/17/2009 | WO2009111846A1 Mitochondrially delivered anti-cancer compounds |
| 09/17/2009 | WO2009111830A1 Conjugated unsaturated compounds |
| 09/17/2009 | WO2009111820A1 Modalmetric fibre sensor |
| 09/17/2009 | WO2009093916A3 Derivatives of aminoalkanols, method of obtaining aminoalkanols and their use |
| 09/17/2009 | WO2009092892A3 Novel composition for treating the side effects of anticancer treatments |
| 09/17/2009 | WO2009091134A3 Pharmaceutical composition for sepsis and septic shock |
| 09/17/2009 | WO2009089338A3 Method and compositions for administering resveratrol and pterostilbene |
| 09/17/2009 | WO2009089070A9 Compositions and methods for reducing particle penetration through mucus |
| 09/17/2009 | WO2009087657A3 Stable pharmaceutical composition of duloxetine and process for its preparation |
| 09/17/2009 | WO2009087410A3 Solid pharmaceutical dosage form |
| 09/17/2009 | WO2009085880A3 C-21 thioethers as glucocorticoid receptor agonists |
| 09/17/2009 | WO2009085766A3 Fenofibric acid amorphous dispersion; method of making; and method of use thereof |
| 09/17/2009 | WO2009084069A3 Ocular solution with organic lycopene |
| 09/17/2009 | WO2009083940A3 Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts |
| 09/17/2009 | WO2009082459A3 Anti-aging composition containing resveratrol and method of administration |
| 09/17/2009 | WO2009082183A3 Vitamin c and vitamin e as an expression enhancer of tyrosine hydroxylase and nurrl for increasing a productivity of dopamine in ventral mesencephalon |
| 09/17/2009 | WO2009080836A3 Macrocyclic indoles as hepatitis c virus inhibitors |
| 09/17/2009 | WO2009080227A3 Pyrazole-carboxamide derivatives as p2y12 antagonists |
| 09/17/2009 | WO2009079562A3 Compositions and methods for treating and preventing skeletal muscle deficiencies |
| 09/17/2009 | WO2009077462A3 Chiral cycloplatinized complexes, method for the production thereof and their use in medicine and catalysts |
| 09/17/2009 | WO2009076399A3 Aminotetralin compounds as mu opioid receptor antagonists |
| 09/17/2009 | WO2009071850A8 Nanoparticles of therapeutic agents having low water solubility |
| 09/17/2009 | WO2009062169A3 Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair |
| 09/17/2009 | WO2009062128A3 Combination drug therapy for the treatment of cancer |
| 09/17/2009 | WO2009051670A3 Oxylipin compounds for the treatment of ophthalmic conditions |
| 09/17/2009 | WO2009044007A3 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamide derivatives, preparation and therapeutic use thereof |
| 09/17/2009 | WO2009038671A3 Oxylipin compounds for treating autoimmune diseases |
| 09/17/2009 | WO2009027785A3 1, 3-oxazole derivatives as cetp inhibitors |
| 09/17/2009 | WO2009006130A3 Salt free hyaluronate ophthalmic solution |
| 09/17/2009 | WO2008099278A8 Pharmaceutical compositions and methods for ccr5 antagonists |
| 09/17/2009 | WO2008076946A9 Methods of neuroprotection by cyclin-dependent kinase inhibition |
| 09/17/2009 | WO2008075380A3 Process for the preparation of thiazolidine derivatives |
| 09/17/2009 | WO2007135241A3 Composition and method for binding acetaldehyde in stomach |
| 09/17/2009 | WO2003007876A3 N-fatty acid-amino acid conjugates and therapeutic uses |
| 09/17/2009 | US20090234271 COMPOSITION COMPRISING siRNA-POLYCATION COMPLEX FOR IONTOPHORESIS |
| 09/17/2009 | US20090234138 Acyloxyalkyl carbamate prodrugs, methods |
| 09/17/2009 | US20090234103 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 09/17/2009 | US20090234024 Estrogenic compounds, process for their production and pharmaceutical uses thereof |
| 09/17/2009 | US20090234023 Substituted hydroxyacetophenone derivatives |
| 09/17/2009 | US20090234022 Formulations of vitamin K analogs for topical use |
| 09/17/2009 | US20090234021 Treatment of Demyelinating Conditions |
| 09/17/2009 | US20090234020 Processes for the preparation of odesmethylvenlafaxine, free from its dimer impurities |
| 09/17/2009 | US20090234019 T Type Calcium Channel Inhibitors |
| 09/17/2009 | US20090234018 Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same |
| 09/17/2009 | US20090234017 Treating skin disorders |
| 09/17/2009 | US20090234016 Compounds for the treatment of metabolic disorders |
| 09/17/2009 | US20090234015 Anti-Inflammatory Quinic Acid Derivatives for Oral Administration |
| 09/17/2009 | US20090234014 Naphthalene-Disulfonamides Useful for the Treatment of Inflammation |
| 09/17/2009 | US20090234013 Pharmaceutical compositions having desirable bioavailability |
| 09/17/2009 | US20090234012 Administration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
| 09/17/2009 | US20090234011 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| 09/17/2009 | US20090234010 Manufacture process of organic compounds |
| 09/17/2009 | US20090234009 Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof |
| 09/17/2009 | US20090234008 Method of using catalpic acid to treat and prevent dyslipidemia, type 2 diabetes, and associated disorders |
| 09/17/2009 | US20090234007 Unsaturated Fatty Acids as Thrombin Inhibitors |
| 09/17/2009 | US20090234006 Method for Producing Arachidonic Acid and/or Eicosapentaenoic Acid in Useful Transgenic Plants |
| 09/17/2009 | US20090234005 Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient |